Skip to content
HSPC Resources for Healthcare Professionals | Wiley Knowledge Hub
  • About
  • Stay Up To Date

HSPC

  • Home
  • Topics
    • Abiraterone Acetate
    • Androgen-Deprivation Therapy
    • Androgen-Receptor Inhibitor
    • Apalutamide
    • Cancer
    • Clinical Trials
    • Conference
    • Darolutamide
    • Docetaxel
    • Doublet Therapy
    • Enzalutamide
    • mCSPC
    • mHSPC
    • Prednisolone
    • Prednisone
    • Prostate-Specific Antigen
    • Radiotherapy
    • Triplet Therapy
  • Webinars
  • Infographics
  • Articles
  • KOL Commentaries
  • Faculty
HSPC Resources for Healthcare Professionals | Wiley Knowledge Hub

HSPC

Search for:
  • Home
  • Topics
    • Abiraterone Acetate
    • Androgen-Deprivation Therapy
    • Androgen-Receptor Inhibitor
    • Apalutamide
    • Cancer
    • Clinical Trials
    • Conference
    • Darolutamide
    • Docetaxel
    • Doublet Therapy
    • Enzalutamide
    • mCSPC
    • mHSPC
    • Prednisolone
    • Prednisone
    • Prostate-Specific Antigen
    • Radiotherapy
    • Triplet Therapy
  • Webinars
  • Infographics
  • Articles
  • KOL Commentaries
  • Faculty
  • About
  • Stay Up To Date

Androgen-Receptor Inhibitor

KOL Commentaries - Androgen-Receptor Inhibitor

Mary-Ellen Taplin mHSPC Summary
KOL Commentary

Primary and novel androgen deprivation therapy for prostate cancer: balancing efficacy and potential toxicities
Mary-Ellen Taplin

VIEW MORE
Mary Taplin HSPC Case Study
Case study

Case Study (2019-2023): Changing treatments
Mary-Ellen Taplin

VIEW MORE
William Oh
Case study

Patient Case Study
William Oh

VIEW MORE

Infographics - Androgen-Receptor Inhibitor

Biomarkers for the Prediction of Disease Progression, Prognosis, and Treatment Response of Metastatic Prostate Cancer

VIEW INFOGRAPHIC

Articles - Androgen-Receptor Inhibitor

Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial

READ MORE

Treatment options for metastatic hormone-sensitive prostate cancer

READ MORE

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

READ MORE

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

READ MORE

Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis

READ MORE

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

READ MORE
Facebook
Twitter
Linkedin

This Knowledge Hub is supported by an educational grant from Astellas, Bayer and Janssen Biotech, Inc. (administered by Janssen Scientific Affairs, LLC)

John Wiley & Sons in partnership with

Knowledge Hub

  • Home
  • Topics
  • On-Demand Webinar
  • Infographics
  • Articles
  • KOL Commentaries
  • Faculty

About

  • About
  • Stay Up To Date
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 John Wiley & Sons, Inc. All rights reserved.

Cookie Preferences

Lost your password?

Start typing and press enter to search